Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | February 26, 2021 | March 03, 2021 |
| Venus Concept Inc.HAIR · Entity 55304 | 10% owner | October 16, 2017 | October 17, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date February 26, 2021 · Filed March 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 848,405 |
Ending reported balance
After 2021-02-26 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2021-02-26 · Exercise / conversion · Acquired 109,749 · Balance 958,154 Row 2 · 2021-02-26 · Exercise / conversion · Acquired 79,363 · Balance 1,037,517 Row 3 · 2021-02-26 · Exercise / conversion · Acquired 45,134 · Balance 1,082,651 Row 4 · 2021-02-26 · Sale · Disposed 170,824 · Balance 911,827 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F2: This sale price represents the weighted average sale price of the shares sold ranging from $30.20 to $31.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Row 5 · 2021-02-26 · Sale · Disposed 43,946 · Balance 867,881 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F3: This sale price represents the weighted average sale price of the shares sold ranging from $31.20 to $32.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Row 6 · 2021-02-26 · Sale · Disposed 15,771 · Balance 852,110 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F4: This sale price represents the weighted average sale price of the shares sold ranging from $32.23 to $33.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Row 7 · 2021-02-26 · Sale · Disposed 3,705 · Balance 848,405 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F5: This sale price represents the weighted average sale price of the shares sold ranging from $33.23 to $33.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.72 · Expires 2025-03-16 | Direct | 0 |
Reported balance
After 2021-02-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-02-26 · Exercise / conversion · Disposed 109,749 · Balance 0 F6: The shares subject to the option are fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.87 · Expires 2026-03-15 | Direct | 0 |
Reported balance
After 2021-02-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-02-26 · Exercise / conversion · Disposed 79,363 · Balance 0 F6: The shares subject to the option are fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.27 · Expires 2027-02-15 | Direct | 0 |
Reported balance
After 2021-02-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-02-26 · Exercise / conversion · Disposed 45,134 · Balance 0 F6: The shares subject to the option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020.
F2: This sale price represents the weighted average sale price of the shares sold ranging from $30.20 to $31.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F3: This sale price represents the weighted average sale price of the shares sold ranging from $31.20 to $32.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F4: This sale price represents the weighted average sale price of the shares sold ranging from $32.23 to $33.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F5: This sale price represents the weighted average sale price of the shares sold ranging from $33.23 to $33.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F6: The shares subject to the option are fully vested and exercisable.
Venus Concept Inc.
Report date October 16, 2017 · Filed October 17, 2017
Jointly reported with ALLOY VENTURES 2002 LLC, KELLY DOUGLAS E, Shoch John, Di Bona Tony, Rubin Daniel, Hanafi Ammar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 12,466 |
Reported balance
After 2017-10-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-10-16 · Conversion · Acquired 12,466 · Balance 12,466 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 26,116 |
Reported balance
After 2017-10-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-10-16 · Conversion · Acquired 13,650 · Balance 26,116 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 42,759 |
Reported balance
After 2017-10-16 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2017-10-16 · Conversion · Acquired 16,643 · Balance 42,759 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 45,041 |
Reported balance
After 2017-10-16 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2017-10-16 · Conversion · Acquired 2,282 · Balance 45,041 F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 461,717 |
Reported balance
After 2017-10-16 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2017-10-16 · Conversion · Acquired 461,717 · Balance 461,717 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 967,297 |
Reported balance
After 2017-10-16 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2017-10-16 · Conversion · Acquired 505,580 · Balance 967,297 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,583,743 |
Reported balance
After 2017-10-16 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2017-10-16 · Conversion · Acquired 616,446 · Balance 1,583,743 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,668,269 |
Reported balance
After 2017-10-16 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2017-10-16 · Conversion · Acquired 84,526 · Balance 1,668,269 F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 474,184 |
Reported balance
After 2017-10-16 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2017-10-16 · Conversion · Acquired 474,184 · Balance 474,184 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 993,414 |
Reported balance
After 2017-10-16 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2017-10-16 · Conversion · Acquired 519,230 · Balance 993,414 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,626,508 |
Reported balance
After 2017-10-16 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2017-10-16 · Conversion · Acquired 633,094 · Balance 1,626,508 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,713,317 |
Reported balance
After 2017-10-16 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2017-10-16 · Conversion · Acquired 86,809 · Balance 1,713,317 F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2017-10-16 · Conversion · Disposed 12,466 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2017-10-16 · Conversion · Disposed 461,717 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2017-10-16 · Conversion · Disposed 474,184 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2017-10-16 · Conversion · Disposed 13,650 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2017-10-16 · Conversion · Disposed 505,580 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2017-10-16 · Conversion · Disposed 519,230 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2017-10-16 · Conversion · Disposed 16,643 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2017-10-16 · Conversion · Disposed 616,446 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2017-10-16 · Conversion · Disposed 633,094 · Balance 0 F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO"). F5: The expiration date is not relevant to the conversion of these securities. F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $7.00 | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2017-10-16 · Conversion · Disposed Not disclosed · Balance 0 F6: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO. F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $7.00 | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2017-10-16 · Conversion · Disposed Not disclosed · Balance 0 F6: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO. F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $7.00 | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-16 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2017-10-16 · Conversion · Disposed Not disclosed · Balance 0 F6: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO. F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO").
F2: See additional Form 4 filed by Alloy Ventures 2002, LLC ("Ventures 2002") for additional members of this joint filing. The securities are directly held by Alloy Partners 2002, L.P. ("Alloy Partners 2002"). Ventures 2002, as the sole general partner of Alloy Partners 2002, may be deemed to beneficially own the securities held by Alloy Partners 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Partners 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
F3: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2002, L.P. ("Alloy Ventures 2002"). Ventures 2002, as the sole general partner of Alloy Ventures 2002, may be deemed to beneficially own the securities held by Alloy Ventures 2002. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona and Daniel Rubin are managing directors of Ventures 2002, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2002. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
F4: See additional Form 4 filed by Ventures 2002 for additional members of this joint filing. The securities are directly held by Alloy Ventures 2005, L.P. ("Alloy Ventures 2005"). Alloy Ventures 2005, LLC ("Ventures 2005"), as the sole general partner of Alloy Ventures 2005, may be deemed to beneficially own the securities held by Alloy Ventures 2005. Craig Taylor, Douglas Kelly, John Shoch, Tony DiBona, Daniel Rubin, Michael Hunkapiller and Ammar H. Hanafi are managing directors of Ventures 2005, and as such may be deemed to beneficially own the securities held by Alloy Ventures 2005. Each Reporting Person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.
F5: The expiration date is not relevant to the conversion of these securities.
F6: The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the "Note"). The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 86,084 | $6.14 | $528,555.76 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 11 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 934,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 45,895 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · derivative · entry 27 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,105 Underlying: Common Stock · 45,895 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over a four year period, provided that the Reporting Person continues to serve through each vesting date. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 45,686 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · derivative · entry 26 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,314 Underlying: Common Stock · 45,686 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 45,967 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · derivative · entry 25 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,033 Underlying: Common Stock · 45,967 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 45,890 | $0.00 Strike: $5.72 | $0.00 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · derivative · entry 24 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,110 Underlying: Common Stock · 45,890 shares Expires 2025-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 45,689 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · derivative · entry 23 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,811 Underlying: Common Stock · 45,689 shares Expires 2024-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 42,114 | $41.06 | $1,729,369.30 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 10 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F6 · price: This sale price represents the weighted average sale price of the shares sold ranging from $40.67 to $41.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 57,902 | $40.28 | $2,332,524.17 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 9 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,519 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F5 · price: This sale price represents the weighted average sale price of the shares sold ranging from $39.67 to $40.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 38,360 | $39.15 | $1,501,640.56 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 8 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 948,421 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F4 · price: This sale price represents the weighted average sale price of the shares sold ranging from $38.67 to $39.66 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 33,491 | $38.08 | $1,275,404.26 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 7 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 986,781 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $37.65 to $38.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 57,260 | $37.17 | $2,128,468.72 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 6 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020,272 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $36.65 to $37.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 45,895 | $2.63 | $120,703.85 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 5 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 45,686 | $5.27 | $240,765.22 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 4 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 45,967 | $7.87 | $361,760.29 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 3 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 985,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 45,890 | $5.72 | $262,490.80 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 2 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 939,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 01:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 45,689 | $6.14 | $280,530.46 |
DisclosureSEC source: 0001299130-21-000087 · certent-form4.xml · nonDerivative · entry 1 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 125,406 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001209191-21-005716 · doc4.xml · derivative · entry 6 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,500 Underlying: Common Stock · 125,406 shares Expires 2024-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 4,916 | $37.77 | $185,657.66 |
DisclosureSEC source: 0001209191-21-005716 · doc4.xml · nonDerivative · entry 5 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F5 · price: This sale price represents the weighted average sale price of the shares sold ranging from $37.63 to $38.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 32,082 | $37.17 | $1,192,359.61 |
DisclosureSEC source: 0001209191-21-005716 · doc4.xml · nonDerivative · entry 4 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 853,321 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F4 · price: This sale price represents the weighted average sale price of the shares sold ranging from $36.62 to $37.61 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 83,241 | $36.01 | $2,997,175.45 |
DisclosureSEC source: 0001209191-21-005716 · doc4.xml · nonDerivative · entry 3 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 885,403 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $35.62 to $36.61 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 5,167 | $35.17 | $181,707.89 |
DisclosureSEC source: 0001209191-21-005716 · doc4.xml · nonDerivative · entry 2 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,644 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $34.61 to $35.60 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 125,406 | $6.14 | $769,992.84 |
DisclosureSEC source: 0001209191-21-005716 · doc4.xml · nonDerivative · entry 1 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 150,857 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · derivative · entry 22 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,906 Underlying: Common Stock · 150,857 shares Expires 2024-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 22, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 35,315 | $37.52 | $1,325,054.12 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 18 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F16 · price: This sale price represents the weighted average sale price of the shares sold ranging from $37.35 to $37.76 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 22, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 70,377 | $36.95 | $2,600,289.40 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 17 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 883,720 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F15 · price: This sale price represents the weighted average sale price of the shares sold ranging from $36.35 to $37.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 22, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 45,165 | $35.92 | $1,622,146.14 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 16 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954,097 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F14 · price: This sale price represents the weighted average sale price of the shares sold ranging from $35.35 to $36.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 22, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 150,857 | $6.14 | $926,261.98 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 15 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 999,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 56,237 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · derivative · entry 21 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,763 Underlying: Common Stock · 56,237 shares Expires 2024-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 152,474 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · derivative · entry 20 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152,474 shares Expires 2023-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 25,993 | $37.13 | $965,068.10 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 14 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,405 F11 · kind: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F13 · price: This sale price represents the weighted average sale price of the shares sold ranging from $36.69 to $37.61 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 23,817 | $36.30 | $864,628.55 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 13 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874,398 F11 · kind: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F12 · price: This sale price represents the weighted average sale price of the shares sold ranging from $35.69 to $36.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 3,656 | $39.09 | $142,894.76 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 12 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,215 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F10 · price: This sale price represents the weighted average sale price of the shares sold ranging from $39.02 to $39.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 700 | $38.06 | $26,638.50 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 11 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,871 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F9 · price: This sale price represents the weighted average sale price of the shares sold ranging from $37.85 to $38.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 61,834 | $37.18 | $2,298,988.12 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 10 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902,571 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F8 · price: This sale price represents the weighted average sale price of the shares sold ranging from $36.85 to $37.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 113,472 | $36.39 | $4,129,473.02 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 9 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 964,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F7 · price: This sale price represents the weighted average sale price of the shares sold ranging from $35.85 to $36.84 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 29,049 | $35.44 | $1,029,380.36 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 8 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,077,877 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F6 · price: This sale price represents the weighted average sale price of the shares sold ranging from $34.85 to $35.84 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 56,237 | $6.14 | $345,295.18 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 7 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,106,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 152,474 | $2.27 | $346,115.98 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 6 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 215,026 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · derivative · entry 19 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,474 Underlying: Common Stock · 215,026 shares Expires 2023-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 20, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 5,949 | $41.41 | $246,318.35 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 5 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,215 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F5 · price: This sale price represents the weighted average sale price of the shares sold ranging from $41.20 to $41.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 20, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 24,032 | $40.69 | $977,862.08 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 4 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,164 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F4 · price: This sale price represents the weighted average sale price of the shares sold ranging from $40.20 to $41.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 20, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 43,846 | $39.35 | $1,725,120.87 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 3 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928,196 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F3 · price: This sale price represents the weighted average sale price of the shares sold ranging from $39.09 to $39.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 20, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 141,199 | $38.79 | $5,476,968.01 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 2 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972,042 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $38.09 to $39.08 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 20, 2021 Filed Jan 23, 2021 02:49 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 215,026 | $2.27 | $488,109.02 |
DisclosureSEC source: 0001299130-21-000032 · certent-form4.xml · nonDerivative · entry 1 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,113,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:34 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 364,451 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001209191-20-065086 · doc4.xml · derivative · entry 17 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 364,451 shares Expires 2022-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:34 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 37,555 | $26.91 | $1,010,529.94 |
DisclosureSEC source: 0001209191-20-065086 · doc4.xml · nonDerivative · entry 13 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,215 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F10 · price: This sale price represents the weighted average sale price of the shares sold ranging from $26.825 to $27.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:34 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 90,459 | $26.34 | $2,382,328.22 |
DisclosureSEC source: 0001209191-20-065086 · doc4.xml · nonDerivative · entry 12 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,770 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F9 · price: This sale price represents the weighted average sale price of the shares sold ranging from $25.83 to $26.82 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:34 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 172,242 | $25.41 | $4,377,013.70 |
DisclosureSEC source: 0001209191-20-065086 · doc4.xml · nonDerivative · entry 11 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,026,229 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F8 · price: This sale price represents the weighted average sale price of the shares sold ranging from $24.83 to $25.82 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:34 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 64,195 | $24.39 | $1,565,844.44 |
DisclosureSEC source: 0001209191-20-065086 · doc4.xml · nonDerivative · entry 10 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,198,471 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020. F7 · price: This sale price represents the weighted average sale price of the shares sold ranging from $23.83 to $24.82 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:34 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 364,451 | $3.01 | $1,096,997.51 |
DisclosureSEC source: 0001209191-20-065086 · doc4.xml · nonDerivative · entry 9 Hunkapiller Michael · CIK 0001317102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.